Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15629MR)

This product GTTS-WQ15629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF13C gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_052945.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 115650
UniProt ID Q96RJ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15629MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5789MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ2708MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ3883MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ573MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ2494MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ5056MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ15791MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ15270MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW